Rapid metabolism of the immuno-PET radioligand [68Ga]Ga-NOTA-GZP upon in vivo administration in mice

Inside the human body, a silent war is often fought by the immune system's elite soldiers: cytotoxic T cells and natural killer cells. When these cells encounter a threat, such as a cancer cell or an infected tissue, they release a specific protein called Granzyme B. This protein acts as a molecular trigger, instructing the target cell to self-destruct. For doctors and researchers, being able to see where and when this protein is active would be a powerful tool. It would allow them to watch the immune system in real time, checking if a new treatment is successfully waking up the body's defenses or if an infection is being contained. To do this, scientists have developed tiny chemical tracers, essentially molecular spies, that can be injected into the body and tracked using a special camera called a PET scanner. These tracers are designed to stick to Granzyme B, lighting up the areas where the immune system is most active.

One of the most promising of these tracers is a molecule labeled with a radioactive form of gallium, a metal that emits signals the camera can detect. Scientists have been using this specific tracer, known as [68Ga]Ga-NOTA-GZP, in mice and even in early human trials to map immune activity. The assumption has been that once injected, this molecule travels through the bloodstream, finds its target, and stays intact long enough to provide a clear picture. However, a recent study conducted by researchers in Norway has uncovered a surprising and critical flaw in this assumption. They found that while the tracer appears perfectly stable in a test tube, it falls apart almost immediately once it enters a living animal. This discovery suggests that the images scientists have been seeing might not be showing the tracer they think they are, but rather the broken pieces of it, which could lead to misinterpretations of how well a treatment is working.

The researchers began their investigation by testing the stability of the tracer in human blood plasma outside the body. They mixed the radioactive molecule with plasma and warmed it to body temperature, mimicking the conditions inside a person. After one hour, they analyzed the mixture and found that the tracer remained completely intact. Every single molecule was still whole, suggesting that the chemical bond holding the radioactive metal to the peptide chain was strong and reliable under these controlled conditions. This result aligned with the confidence many scientists had placed in the tool, reinforcing the idea that it was a robust agent for imaging.

However, the story changed dramatically when the team moved from the test tube to living mice. They injected the same tracer into healthy mice and tumor-bearing mice, then drew blood samples at specific intervals: fifteen minutes, thirty minutes, and sixty minutes after the injection. When they analyzed these blood samples, the picture was starkly different. Within just fifteen minutes, the amount of intact tracer in the blood had dropped to roughly thirteen percent. By thirty minutes, it was down to less than five percent, and by the hour mark, almost none of the original molecule remained. Instead of a single, clean signal, the blood contained a mix of new, smaller radioactive fragments. The tracer had been rapidly dismantled by the body's biological processes.

To understand what these fragments were, the researchers compared them to known substances. One of the new fragments appeared in the analysis at a time very similar to free gallium, the metal without its peptide carrier, or a small piece of the carrier molecule itself. This suggested that the metal had detached from the peptide chain, a process known as demetallation, or that the chain had been cut into pieces. Another fragment appeared slightly earlier than the original tracer, which the researchers hypothesized might be the result of the body's enzymes chemically altering the end of the peptide molecule, perhaps turning a specific chemical group into an acid. Crucially, when they compared the behavior of the original tracer to the behavior of free gallium injected directly into mice, the two looked nothing alike. The free gallium accumulated heavily in the liver and stayed there, while the tracer and its fragments were quickly washed out through the kidneys and into the bladder. This difference proved that the broken pieces were not simply acting like free metal; they were behaving like small, water-soluble fragments that the body filtered out rapidly.

The implications of these findings are significant for how scientists interpret images of the immune system. Many previous studies have relied on mathematical models to calculate exactly how much tracer is binding to a tumor, assuming that the signal in the blood comes from the intact molecule. If the molecule breaks down so quickly, those calculations are likely incorrect because the camera is detecting a mixture of the original tracer and its fragments. The researchers noted that this rapid breakdown happens much faster than previously reported in other studies, which may have only looked at a single point in time and missed the speed of the degradation. They also pointed out that the chemical structure of the tracer can vary slightly depending on how it is made, and these small differences might explain why some earlier studies saw better stability than others.

Ultimately, this study serves as a vital reality check for the field of immune imaging. It demonstrates that a molecule can be perfectly stable in a test tube yet fragile in a living body, and that what looks like a successful image might actually be a collection of metabolic debris. The researchers conclude that to get a true understanding of immune activity, future studies must account for this rapid breakdown. They suggest that scientists need to design more stable tracers that can survive the journey through the bloodstream and to be very careful when interpreting data from existing tracers. Without these corrections, the pictures we see of the immune system fighting disease might be blurry, showing the aftermath of a battle rather than the battle itself.